836 Results
Sort By:
Published on August 27, 2018
Centogene AG has entered a global strategic collaboration for joint drug discovery projects, focused on rare genetic diseases. The collaboration aims to develop a strategic high-throughput platform for testing novel small molecules in rare hereditary metabolic diseases. The development project will leverage Evotec’s induced pluripotent stem cell (iPSC) platform and broad…
Published on August 13, 2018
Scientists at University of Utah (U of U) Health report that they have developed high-tech tools to uncover the genetic cause of early infantile epileptic encephalopathy (EIEE). Their study (“Whole-genome analysis for effective clinical diagnosis and gene discovery in early infantile epileptic encephalopathy”) appears online in Nature Genomic Medicine. “Early infantile epileptic encephalopathy (EIEE)…
Published on August 8, 2018
BC Platforms said today its genomic data management platform will be used by the Finnish genetic testing and analyzing technology company Negen toward the early risk assessment of common diseases, through an agreement whose value was not disclosed. The companies plan to develop a combined solution for healthcare providers and…
Published on August 7, 2018
Boston Children’s Hospital said today it plans to sequence the DNA of 3,000 patients with epilepsy or inflammatory bowel disease and their family members, in what it called a strategic initiative to expand its research genomics gateway. Patients with epilepsy or inflammatory bowel disease of likely genetic origin, undiagnosed after…
Published on August 2, 2018
New technologies and computational methods are introduced virtually every day to improve the use of “omics” in diagnostics and precision medicine. While most of these are either genuine improvements to existing technologies or represent a new method or technique, the vast majority of these introductions only effect incremental change. However,…
Published on August 1, 2018
Mammoth Biosciences, a startup created to develop a CRISPR-enabled platform capable of detecting any biomarker or disease containing DNA or RNA, has completed a $23 million Series A financing. Mammoth—whose co-founders include CRISPR pioneer Jennifer Doudna, Ph.D.—said the financing will enable the company to build out its IP portfolio, expand…
Published on July 30, 2018
Konica Minolta Precision Medicine, a new company division formed recently with the acquisitions of Ambry Genetics and Invicro, has named John E. Niederhuber, M.D., as the chairman of their Scientific Advisory Board. Since 2010 Neiderhuber has been executive vice president and CEO of Inova Translational Medicine Institute (TMI) and was…
Published on July 26, 2018
Agendia said it has completed a $35 million financing designed to help the company accelerate its commercial expansion in and outside the U.S., invest more in big data trials, and establish collaborations with academic institutions. A developer of genomic diagnostics focused on precision oncology, Agendia said its planned expansion would…
Published on July 25, 2018
23andMe has received a $300 million equity investment disclosed today by GlaxoSmithKline (GSK), under a collaboration designed to use genetic data to identify new drug targets, and thus accelerate development of new therapies for both companies. The collaboration is intended to combine 23andMe’s expertise in gathering and analyzing data from…
Published on July 24, 2018
The last 10 years have seen enormous progress in both the understanding of cancer as a disease, as well as the development of targeted therapies, with an unprecedented number of new drugs approved for cancer treatment by the FDA and EMA. The availability of a large set of targeted therapies…
Published on June 27, 2018
UPMC and the University of Pittsburgh have launched an advanced genome sequencing center designed to support clinical diagnostics and research initiatives in precision medicine and immunotherapy. The UPMC Genome Center is intended to provide clinicians and researchers with access to a large-scale genomics facility that has undergone validation testing and…
Published on June 21, 2018
A University of California, San Diego (UCSD)-led research team has discovered that a small subset of diverse solid tumor ]types harbour amplifications in the programmed cell death ligand 1 (PDL1) gene, a finding that could help to identify additional cancer patients who will respond to treatment with immune checkpoint inhibitors…
Published on June 20, 2018
The UK National Institute for Health Research’s Invention for Innovation program has awarded molecular diagnostics developer Genedrive £550,000 (about $725,000) as part of a larger multi-partner grant award to develop and implement a point-of-care pharmacogenetic test to avoid antibiotic-related hearing loss in newborn children. The grant will go toward funding…
Published on June 20, 2018
Signaling growing interest in personalized oncology treatments as well as diagnostics, Roche plans a $2.4 billion acquisition that will expand its majority stake in Foundation Medicine into full ownership of the cancer-focused molecular diagnostics developer. Under the deal, Roche and Foundation Medicine said, they plan to combine their expertise in…
Published on June 13, 2018
The FDA has approved an additional use for Agilent Technologies’ Dako PD-L1 IHC 22C3 pharmDx assay, expanding its approvals to include another indication for the multi-indication Merck & Co.’s blockbuster anti-programmed cell death protein 1 (PD-1) cancer immunotherapy Keytruda (pembrolizumab). Dako PD-L1 IHC 22C3 pharmDx is now the first FDA-approved…